EANS-News: Intercell completed the acquisition of Cytos' antibody technology platform

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Vienna (Austria), June 8, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) today
announced the closing of the acquisition of Cytos' platform technology for
monoclonal antibody discovery. On May 6, 2010 Intercell had announced the intent
to acquire that technology, which is based on expression cloning of monoclonal
antibodies from human B-cells, for EUR 15m.

The antibody technology complements Intercell's technology platforms and opens
novel medically and commercially relevant applications for Intercell's Antigen
Identification Program (AIP®).

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wien
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print